Cover Image

In silico Docking Analysis of Bromelain Compound with Cancer Cell-Surface Receptor Proteins

Bromelain compound is a bioactive compound belonging to the cysteine protease family which can be isolated Bromelain compound is a bioactive compound belonging to the cysteine protease family which can be isolated from the stem of Ananas comosus (pineapple). The compound is known for carrying phyto...

Full description

Saved in:
Bibliographic Details
Main Author: Nurhazimah, Hasbi
Format: Final Year Project Report
Language:English
Published: Universiti Malaysia Sarawak, (UNIMAS) 2022
Subjects:
RC Internal medicine
Online Access:http://ir.unimas.my/id/eprint/39656/1/NURHAZIMAH%20BINTI%20HASBI_ft.pdf
http://ir.unimas.my/id/eprint/39656/
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.unimas.ir.39656
record_format eprints
institution Universiti Malaysia Sarawak
building Centre for Academic Information Services (CAIS)
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Malaysia Sarawak
content_source UNIMAS Institutional Repository
url_provider http://ir.unimas.my/
language English
topic RC Internal medicine
spellingShingle RC Internal medicine
Nurhazimah, Hasbi
In silico Docking Analysis of Bromelain Compound with Cancer Cell-Surface Receptor Proteins
description Bromelain compound is a bioactive compound belonging to the cysteine protease family which can be isolated Bromelain compound is a bioactive compound belonging to the cysteine protease family which can be isolated from the stem of Ananas comosus (pineapple). The compound is known for carrying phytomedicine properties for treating various diseases including cancer through induction of apoptosis. The present research focuses on the insilico docking analysis of bromelain compound with cancer cell surface-receptor protein to study the best binding mode and the specific binding sites of the interaction on different cancer cell surface receptor proteins which are HER2, VEGFR1, CD44, TNFR-1A and EGFR. The docking process which was carried out through Autodock Vina Bromelain compound is a bioactive compound belonging to the cysteine protease family which can be isolated from the stem of Ananas comosus (pineapple). The compound is known for carrying phytomedicine properties for treating various diseases including cancer through induction of apoptosis. The present research focuses on the insilico docking analysis of bromelain compound with cancer cell surface-receptor protein to study the best binding mode and the specific binding sites of the interaction on different cancer cell surface receptor proteins which are HER2, VEGFR1, CD44, TNFR-1A and EGFR. The docking process which was carried out through Autodock Vina Bromelain compound is a bioactive compound belonging to the cysteine protease family which can be isolated from the stem of Ananas comosus (pineapple). The compound is known for carrying phytomedicine properties for treating various diseases including cancer through induction of apoptosis. The present research focuses on the insilico docking analysis of bromelain compound with cancer cell surface-receptor protein to study the best binding mode and the specific binding sites of the interaction on different cancer cell surface receptor proteins which are HER2, VEGFR1, CD44, TNFR-1A and EGFR. The docking process which was carried out through Autodock Vina shows that the binding affinity of the receptor ligand complex of bromelain with HER2, VEGFR1, CD44, EGFR and TNFR-1A were -8.9, -8.9, -7.8, -7.7 and -7.1 respectively. The result shows promising binding affinity of the interacting receptor-ligand complex and further study on the efficacy of bromelain compound in cancer treatment research should be conducted. shows that the binding affinity of the receptor ligand complex of bromelain with HER2, VEGFR1, CD44, EGFR and TNFR-1A were -8.9, -8.9, -7.8, -7.7 and -7.1 respectively. The result shows promising binding affinity of the interacting receptor-ligand complex and further study on the efficacy of bromelain compound in cancer treatment research should be conducted. shows that the binding affinity of the receptor ligand complex of bromelain with HER2, VEGFR1, CD44, EGFR and TNFR-1A were -8.9, -8.9, -7.8, -7.7 and -7.1 respectively. The result shows promising binding affinity of the interacting receptor-ligand complex and further study on the efficacy of bromelain compound in cancer treatment research should be conducted. from the stem of Ananas comosus (pineapple). The compound is known for carrying phytomedicine properties for treating various diseases including cancer through induction of apoptosis. The present research focuses on the insilico docking analysis of bromelain compound with cancer cell surface-receptor protein to study the best binding mode and the specific binding sites of the interaction on different cancer cell surface receptor proteins which are HER2, VEGFR1, CD44, TNFR-1A and EGFR. The docking process which was carried out through Autodock Vina shows that the binding affinity of the receptor ligand complex of bromelain with HER2, VEGFR1, CD44, EGFR and TNFR-1A were -8.9, -8.9, -7.8, -7.7 and -7.1 respectively. The result shows promising binding affinity of the interacting receptor-ligand complex and further study on the efficacy of bromelain compound in cancer treatment research should be conducted.
format Final Year Project Report
author Nurhazimah, Hasbi
author_facet Nurhazimah, Hasbi
author_sort Nurhazimah, Hasbi
title In silico Docking Analysis of Bromelain Compound with Cancer Cell-Surface Receptor Proteins
title_short In silico Docking Analysis of Bromelain Compound with Cancer Cell-Surface Receptor Proteins
title_full In silico Docking Analysis of Bromelain Compound with Cancer Cell-Surface Receptor Proteins
title_fullStr In silico Docking Analysis of Bromelain Compound with Cancer Cell-Surface Receptor Proteins
title_full_unstemmed In silico Docking Analysis of Bromelain Compound with Cancer Cell-Surface Receptor Proteins
title_sort in silico docking analysis of bromelain compound with cancer cell-surface receptor proteins
publisher Universiti Malaysia Sarawak, (UNIMAS)
publishDate 2022
url http://ir.unimas.my/id/eprint/39656/1/NURHAZIMAH%20BINTI%20HASBI_ft.pdf
http://ir.unimas.my/id/eprint/39656/
_version_ 1744357790344806400
spelling my.unimas.ir.396562022-09-12T09:19:34Z http://ir.unimas.my/id/eprint/39656/ In silico Docking Analysis of Bromelain Compound with Cancer Cell-Surface Receptor Proteins Nurhazimah, Hasbi RC Internal medicine Bromelain compound is a bioactive compound belonging to the cysteine protease family which can be isolated Bromelain compound is a bioactive compound belonging to the cysteine protease family which can be isolated from the stem of Ananas comosus (pineapple). The compound is known for carrying phytomedicine properties for treating various diseases including cancer through induction of apoptosis. The present research focuses on the insilico docking analysis of bromelain compound with cancer cell surface-receptor protein to study the best binding mode and the specific binding sites of the interaction on different cancer cell surface receptor proteins which are HER2, VEGFR1, CD44, TNFR-1A and EGFR. The docking process which was carried out through Autodock Vina Bromelain compound is a bioactive compound belonging to the cysteine protease family which can be isolated from the stem of Ananas comosus (pineapple). The compound is known for carrying phytomedicine properties for treating various diseases including cancer through induction of apoptosis. The present research focuses on the insilico docking analysis of bromelain compound with cancer cell surface-receptor protein to study the best binding mode and the specific binding sites of the interaction on different cancer cell surface receptor proteins which are HER2, VEGFR1, CD44, TNFR-1A and EGFR. The docking process which was carried out through Autodock Vina Bromelain compound is a bioactive compound belonging to the cysteine protease family which can be isolated from the stem of Ananas comosus (pineapple). The compound is known for carrying phytomedicine properties for treating various diseases including cancer through induction of apoptosis. The present research focuses on the insilico docking analysis of bromelain compound with cancer cell surface-receptor protein to study the best binding mode and the specific binding sites of the interaction on different cancer cell surface receptor proteins which are HER2, VEGFR1, CD44, TNFR-1A and EGFR. The docking process which was carried out through Autodock Vina shows that the binding affinity of the receptor ligand complex of bromelain with HER2, VEGFR1, CD44, EGFR and TNFR-1A were -8.9, -8.9, -7.8, -7.7 and -7.1 respectively. The result shows promising binding affinity of the interacting receptor-ligand complex and further study on the efficacy of bromelain compound in cancer treatment research should be conducted. shows that the binding affinity of the receptor ligand complex of bromelain with HER2, VEGFR1, CD44, EGFR and TNFR-1A were -8.9, -8.9, -7.8, -7.7 and -7.1 respectively. The result shows promising binding affinity of the interacting receptor-ligand complex and further study on the efficacy of bromelain compound in cancer treatment research should be conducted. shows that the binding affinity of the receptor ligand complex of bromelain with HER2, VEGFR1, CD44, EGFR and TNFR-1A were -8.9, -8.9, -7.8, -7.7 and -7.1 respectively. The result shows promising binding affinity of the interacting receptor-ligand complex and further study on the efficacy of bromelain compound in cancer treatment research should be conducted. from the stem of Ananas comosus (pineapple). The compound is known for carrying phytomedicine properties for treating various diseases including cancer through induction of apoptosis. The present research focuses on the insilico docking analysis of bromelain compound with cancer cell surface-receptor protein to study the best binding mode and the specific binding sites of the interaction on different cancer cell surface receptor proteins which are HER2, VEGFR1, CD44, TNFR-1A and EGFR. The docking process which was carried out through Autodock Vina shows that the binding affinity of the receptor ligand complex of bromelain with HER2, VEGFR1, CD44, EGFR and TNFR-1A were -8.9, -8.9, -7.8, -7.7 and -7.1 respectively. The result shows promising binding affinity of the interacting receptor-ligand complex and further study on the efficacy of bromelain compound in cancer treatment research should be conducted. Universiti Malaysia Sarawak, (UNIMAS) 2022 Final Year Project Report NonPeerReviewed text en http://ir.unimas.my/id/eprint/39656/1/NURHAZIMAH%20BINTI%20HASBI_ft.pdf Nurhazimah, Hasbi (2022) In silico Docking Analysis of Bromelain Compound with Cancer Cell-Surface Receptor Proteins. [Final Year Project Report] (Unpublished)
score 13.211869

Similar Items